$PPBT +25% Premarket 🚀 🔹 Purple Biotech gaining attention after Q1 update highlighted progress across its CAPTN-3 tri-specific antibody platform 📈 🔹 Lead ca

$PPBT +25% Premarket 🚀 🔹 Purple Biotech gaining attention after Q1 update highlighted progress across its CAPTN-3 tri-specific antibody platform 📈 🔹 Lead candidate IM1240 showed anti-tumor activity across treatment-resistant patient-derived tumor samples 🧬 🔹 Company is targeting solid tumors t…